Malignant mesothelioma versus synovial sarcoma: an analysis of 19 cases with molecular diagnosis

Sonja Klebe, Sarita Prabhakaran, Ashleigh Hocking, Philip Allen, Douglas Henderson

    Research output: Contribution to journalMeeting Abstract


    Intrathoracic synovial sarcomas (SSas) are well documented in the literature and characterized by a distinctive t(X;18) translocation. The histologic appearances of a monophasic or biphasic SSa can lead to confusion with biphasic or sarcomatoid mesothelioma (MM). The distinction of pleural SSa from pleural MM is important, because SSas may be responsive to ifosfamide-based chemotherapy and have no proven causal relationship to prior asbestos exposure. Demonstration of the t(X;18) by cytogenetics, fluorescence in situ hybridization (FISH) or reverse-transcriptase polymerase chain reaction is the gold standard for diagnosis, but availability of molecular diagnosis can be limited and testing is time consuming. Recently, it has been suggested that immunohistochemistry (IHC) for transducin-like enhancer of split 1 (TLE) is reliable for diagnosis of SSa and may replace molecular diagnosis.
    Original languageEnglish
    Pages (from-to)S2018
    Number of pages1
    JournalJournal of Thoracic Oncology
    Issue number11 (suppl. 2)
    Publication statusPublished - Nov 2017
    Event18th World Conference on Lung Cancer: International Association for the Study of Lung Cancer (IASLC) - Yokohama, Japan
    Duration: 15 Oct 201718 Oct 2017


    • Pathology Diagnosis
    • Mesothelioma
    • Synovial sarcoma


    Dive into the research topics of 'Malignant mesothelioma versus synovial sarcoma: an analysis of 19 cases with molecular diagnosis'. Together they form a unique fingerprint.

    Cite this